Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Assertio Holdings, Inc.

Market Cap 152M 131M 120M 113M 212M 14.35B 214M 1.42B 556M 7.03B 570M 558M 24.32B P/E Ratio 2026 *
-7.48x
P/E Ratio 2027 * 61.8x
Enterprise Value 152M 131M 120M 113M 212M 14.35B 214M 1.42B 556M 7.03B 570M 558M 24.32B EV / Sales 2026 *
1.43x
EV / Sales 2027 * 1.32x
Free-Float
98.03%
Yield 2026 *
-
Yield 2027 * -
1 day+0.09%
1 week+0.30%
Current month+0.26%
1 month+0.77%
3 months+103.64%
6 months+112.31%
Current year+159.10%
1 week 23.47
Extreme 23.47
23.5
1 month 23.32
Extreme 23.32
23.5
Current year 9.11
Extreme 9.11
23.5
1 year 8.61
Extreme 8.61
23.5
3 years 7.71
Extreme 7.7055
96.15
5 years 7.71
Extreme 7.7055
120.15
10 years 7.71
Extreme 7.7055
1,621.19
Manager TitleAgeSince
Chief Executive Officer 61 28/10/2025
Director of Finance/CFO 42 08/11/2023
Director of Finance/CFO 55 11/03/2021
Director TitleAgeSince
Director/Board Member 64 01/03/2017
Chairman 65 07/11/2024
Director/Board Member 48 14/11/2023
Date Insider Type Main position Quantity % Market Cap.
05-13Don

Chairman

-13,332 0.2069%
05-05Free

Director

4,851 0.0753%
05-05Free

Director

4,851 0.0753%
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+0.30%+147.93%-74.48% 152M
-0.18%-1.74%+39.28%+151.23% 1,007B
-1.14%-1.76%+49.99%+41.76% 567B
-0.43%-2.33%+15.35%+58.80% 392B
-0.71%+1.05%+20.91%+18.37% 328B
-0.67%+0.91%+23.96%+31.62% 277B
+0.68%-2.57%+22.78%+12.67% 275B
-1.86%+4.12%-43.67%-49.16% 196B
-0.71%+0.87%+17.59%+51.33% 189B
+1.92%+0.69%+14.02%+60.25% 154B
Average -0.25%+0.31%+30.81%+30.24% 338.62B
Weighted average by Cap. -0.38%-0.03%+26.77%+66.93%

Financials

2026 *2027 *
Net sales 106M 91.24M 83.97M 78.78M 148M 10B 149M 993M 388M 4.9B 397M 389M 16.95B 115M 99.3M 91.39M 85.74M 161M 10.89B 163M 1.08B 422M 5.33B 432M 423M 18.45B
Net income -20.22M -17.43M -16.04M -15.05M -28.27M -1.91B -28.55M -190M -74.07M -936M -75.89M -74.28M -3.24B 2.85M 2.46M 2.26M 2.12M 3.99M 270M 4.03M 26.77M 10.46M 132M 10.71M 10.49M 457M
Net Debt - -
Logo Assertio Holdings, Inc.
Assertio Holdings, Inc. is a pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.
Employees
53
Date Price Change Volume
15/06/26 23.50 $ +0.09% 274,343
12/06/26 23.48 $ +0.04% 486,525
11/06/26 23.47 $ -0.04% 298,118
10/06/26 23.48 $ +0.09% 439,224
09/06/26 23.46 $ +0.13% 547,036
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
23.50USD
Average target price
24.43USD
Spread / Average Target
+3.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASRT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!